pathology studied is schizophrenia
Conditions
Brief summary
The main evaluation criterion is the level of microglial activation measured in PET with [ 18F]-DPA714 in the brain, which will be compared between groups according to the genotype of C4 weighted by the ancestral haplotype that carries it
Detailed description
- Regional cortical thicknesses as determined on anatomical MRI, Parameters of subcortical brain connectivity (variables derived from diffusion MRI such as fractional anisotropy and resting functional MRI such as functional connectivity) which will be compared between groups according to the C4 genotype., Lipid abnormalities (cholesterol, serum triglycerides), blood glucose, peripheral markers of inflammation (CRP, cytokines) and clinical parameters (abdominal tension, abdominal girth) will also be correlated to the level of microglial activation measured in PET
Interventions
DRUG18F-DPA-714
Sponsors
Institut National De La Sante Et De La Recherche Medicale
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main evaluation criterion is the level of microglial activation measured in PET with [ 18F]-DPA714 in the brain, which will be compared between groups according to the genotype of C4 weighted by the ancestral haplotype that carries it | — |
Secondary
| Measure | Time frame |
|---|---|
| - Regional cortical thicknesses as determined on anatomical MRI, Parameters of subcortical brain connectivity (variables derived from diffusion MRI such as fractional anisotropy and resting functional MRI such as functional connectivity) which will be compared between groups according to the C4 genotype., Lipid abnormalities (cholesterol, serum triglycerides), blood glucose, peripheral markers of inflammation (CRP, cytokines) and clinical parameters (abdominal tension, abdominal girth) will also be correlated to the level of microglial activation measured in PET | — |
Countries
France
Outcome results
None listed